The myCare-022-03 study demonstrated that the Cellworks Singulaä Therapy Response Index is strongly predictive of overall survival and disease-free survival for glioblastoma patients.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe